Cinacalcet for the treatment of secondary hyperparathyroidism. Systematic review [Cinacalcet para el tratamiento de hiperparatiroidismo secundario. Revisión sistemática]
DOI:
https://doi.org/10.62574/jzczvy61Keywords:
Cinacalcet, parathyroid glands, endocrine glandsAbstract
Objective: to analyse the use of Cinacalcet for the treatment of secondary hyperparathyroidism. Method: Systematic review. Results and conclusion: Cinacalcet is an effective and safe therapeutic intervention for the management of secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis, as it modulates parathyroid hormone levels, reduces bone and cardiovascular complications, and offers a non-invasive alternative to parathyroidectomy. Advances in its synthesis through more sustainable processes and the application of tools such as machine learning have optimised its clinical evaluation and availability.
Downloads
References
Rathod VD, Paganelli S, Kočevar M, Krivec M, Piccolo O. Improved process for the synthesis of 3-(3-trifluoromethylphenyl)propanal for more sustainable production of cinacalcet HCl. Molecules. 2023;28(16):6042. Available from: https://www.mdpi.com/1420-3049/28/16/6042/htm
Alvarado L, Sharma N, Lerma R, et al. Parathyroidectomy versus cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients. World J Surg. 2022;46(4):813-819. Available from: https://onlinelibrary.wiley.com/doi/full/10.1007/s00268-022-06439-7
Ponce D, de Almeida Cardoso MM, Rúgolo JRM, et al. Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease. Braz J Nephrol. 2023;45(3):369-376. Available from: https://www.scielo.br/j/jbn/a/ny3NBkQRMqnLKKyzZC7ssWK/?lang=en
Wang AX, Liu S, Montez-Rath ME, Chertow GM, Lenihan CR. Parathyroidectomy and cinacalcet use in Medicare-insured kidney transplant recipients. Am J Kidney Dis. 2023;81(3):270-280.e1. Available from: http://www.ajkd.org/article/S0272638622009155/fulltext
Nakamura H, Tokumoto M, Anayama M, et al. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. CEN Case Rep. 2022;11(2):254. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061916/
Li X, Ding W, Zhang H. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. Front Endocrinol (Lausanne). 2023;14:1146955.
Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of cinacalcet and etelcalcetide on bone mineral and cardiovascular disease in dialysis patients. Curr Osteoporos Rep. 2023;21(2):193-204. Available from: https://link.springer.com/article/10.1007/s11914-023-00782-x
Komaba H, Hamano T, Fujii N, et al. Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab. 2022;107(7):2016-2025. Available from: https://dx.doi.org/10.1210/clinem/dgac142
Al-Homrany M, Saeed M, Ali F, et al. The effectiveness of alternate-day cinacalcet therapy for secondary hyperparathyroidism in noncompliant hemodialysis patients. Saudi J Kidney Dis Transpl. 2022;33(4):503-508. Available from: https://journals.lww.com/sjkd/fulltext/2022/33040/the_effectiveness_of_alternate_day_cinacalcet.1.aspx
Liu J, Guo H, Lin TC, et al. Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiol Drug Saf. 2022;31(2):141-148. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5337
Wakamatsu T, Yamamoto S, Matsuo K, et al. Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials. J Bone Miner Metab. 2024;42(3):316-325. Available from: https://link.springer.com/article/10.1007/s00774-024-01500-y
Zamoner SMS, Takase HM, Riyuzo MC, et al. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series. Int Urol Nephrol. 2024;56(5):1669-1676. Available from: https://link.springer.com/article/10.1007/s11255-023-03844-2
Villarroel-Heise P, Ardiles-Arnaiz L, Cifuentes-Köster M, et al. Uso de cinacalcet en hiperparatiroidismo secundario: evaluación del estado nutricional, lipídico e inflamatorio en enfermedad renal crónica. Nutr Hosp. 2023;40(6):1236-1245.
Parksook WW, Heydarpour M, Brown JM, Turchin A, Mannstadt M, Vaidya A. Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial. Clin Endocrinol (Oxf). 2023;98(4):516-526. doi:10.1111/cen.14840
Leere JS, Karmisholt J, Robaczyk M, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407-417. doi:10.1016/S2213-8587(20)30063-2
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Karen Gabriela Sulca-Espín, John Sebastián Carvajal-Gavilanes, Miguel Alejandro Alvarado-Salán, Alex Ramón Valencia-Herrera
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
